title: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
abstract: OBJECTIVE
  To evaluate whether two commonly used newer platinum-based regimens offer any advantage over vinorelbine-cisplatin (reference regimen) in response rate for patients with advanced non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Chemotherapy-naive patients were randomized to receive gemcitabine 1,250 mg/m(2) days 1 and 8 plus cisplatin 75 mg/m(2) day 2 every 21 days (GC arm), or paclitaxel 225 mg/m(2) (3-hour infusion) then carboplatin (area under the concentration-time curve of 6 mg/mL x min), both on day 1 every 21 days (PCb arm), or vinorelbine 25 mg/m(2)/wk for 12 weeks then every other week plus cisplatin 100 mg/m(2) day 1 every 28 days (VC arm).
  
  
  RESULTS
  Six hundred twelve patients were randomized to treatment (205 GC, 204 PCb, and 203 VC). Overall response rates for the GC (30%) and PCb (32%) arms were not significantly different from that of the VC arm (30%). There were no differences in overall survival, time to disease progression, or time to treatment failure. Median survival for the GC, PCb, and VC groups was 9.8, 9.9, and 9.5 months, respectively. Neutropenia was significantly higher on the VC arm (GC 17% or PCb 35% v VC 43% of cycles, P <.001), as was thrombocytopenia on the GC arm (GC 16% v VC 0.1% of cycles, P <.001). Alopecia and peripheral neurotoxicity were most common on the PCb arm, as was nausea/vomiting on the VC arm (P <.05).
  
  
  CONCLUSIONS
  Efficacy end points were not significantly different between experimental and reference arms, although toxicities showed differences. These findings suggest that chemotherapy in NSCLC has reached a therapeutic plateau.
authors.affiliation: Department of Clinical and Biological Sciences, University of Torino, Turin. scagliotti@ihnet.it
authors.forename: G V
authors.initials: GV
authors.lastname: Scagliotti
authors.forename: F
authors.initials: F
authors.lastname: De Marinis
authors.forename: M
authors.initials: M
authors.lastname: Rinaldi
authors.forename: L
authors.initials: L
authors.lastname: Crinò
authors.forename: C
authors.initials: C
authors.lastname: Gridelli
authors.forename: S
authors.initials: S
authors.lastname: Ricci
authors.forename: E
authors.initials: E
authors.lastname: Matano
authors.forename: C
authors.initials: C
authors.lastname: Boni
authors.forename: M
authors.initials: M
authors.lastname: Marangolo
authors.forename: G
authors.initials: G
authors.lastname: Failla
authors.forename: G
authors.initials: G
authors.lastname: Altavilla
authors.forename: V
authors.initials: V
authors.lastname: Adamo
authors.forename: A
authors.initials: A
authors.lastname: Ceribelli
authors.forename: M
authors.initials: M
authors.lastname: Clerici
authors.forename: F
authors.initials: F
authors.lastname: Di Costanzo
authors.forename: L
authors.initials: L
authors.lastname: Frontini
authors.forename: M
authors.initials: M
authors.lastname: Tonato
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage; D016019:Survival Analysis; D013921:Thrombocytopenia / Q000139:chemically induced; D016896:Treatment Outcome; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D014747:Vinblastine; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin; D000077235:Vinorelbine; D000093542:Gemcitabine